Wednesday, February 10, 2010, 7:53pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Keryx Biopharmaceuticals Inc. (KERX)

At 5:00AM SGT: 2.31 USD   0.00 (0.00%)  
 MORE ON KERX 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Keryx Biopharmaceuticals, Inc. (NCM:KERX) Delayed quote dataEdit
Last Trade:2.31 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:2.31
Open:N/A
Bid:2.19 x 200
Ask:2.88 x 1000
1y Target Est:5.00
Day's Range:N/A - N/A
52wk Range:0.09 - 3.45
Volume:0
Avg Vol (3m):1,774,390
Market Cap:129.31M
P/E (ttm):9.75
EPS (ttm):0.24
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add KERX to Portfolio   Download Data

 HEADLINES 
•A Triple in the Making
at Motley Fool (Mon, Feb 8)
•Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
Marketwire (Sat, Feb 6)
•Biotech Stock Mailbag: Soligenix
at TheStreet.com (Fri, Feb 5)
•Biopharmaceutical Stock Alert for Keryx Biopharmaceuticals Inc. Issued by InvestorSoup
GlobeNewswire (Fri, Feb 5)
•Keryx, FDA agree on colon cancer drug study goals
AP (Thu, Feb 4)
•Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
PR Newswire (Wed, Feb 3)
•Keryx Biopharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
PR Newswire (Tue, Feb 2)
•Keryx, AEterna see positive perifosine data
AP (Fri, Jan 29)
•Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia
PR Newswire (Fri, Jan 29)
•Biotech Stock Mailbag: Keryx Biopharmaceuticals
at TheStreet.com (Fri, Jan 29)
More Headlines for KERX...
 ANALYST 
EPS Est (next year) (Dec-09) :0.23
EPS Est (in 2 years) (Dec-10) :-0.26
Avg Rec (current)*:1.0
PEG Ratio:0.42
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices